Alnylam Pharmaceuticals Financial Ratios
NASDAQ: ALNYHealth CareBiotechnology: Pharmaceutical PreparationsUSD
232.68+8.15 (+3.63%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Alnylam Pharmaceuticals ratio analysis
Alnylam Pharmaceuticals earned a net margin of 8.4% in FY 2025, up from -12.4% a year earlier. Gross margin was 81.8% compared with a median of 86.4% over the prior 8 years. Return on equity reached 39.8%, meaning Alnylam Pharmaceuticals generated 0.40 dollars of profit for every dollar of shareholders' equity.
Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Alnylam Pharmaceuticals financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| P/E ratio (at fiscal year end) | 171.75 | — | — | — | — | — | — | — | — | — |
| Price / sales | 14.12 | 13.30 | 13.08 | 27.88 | 23.79 | 30.32 | 57.52 | 100.98 | 127.96 | 67.96 |
| Price / book | 66.43 | 445.77 | — | — | 34.15 | 14.71 | 8.79 | 5.81 | 6.51 | 3.48 |
| Gross margin | 81.8% | 86.4% | 85.3% | 86.5% | 86.4% | 84.9% | 88.6% | 97.6% | 100.0% | — |
| Operating margin | 13.5% | -7.9% | -15.4% | -75.7% | -83.9% | -168.1% | -427.5% | -1,087.6% | -556.2% | -900.3% |
| Net margin | 8.4% | -12.4% | -24.1% | -109.0% | -101.0% | -174.1% | -403.2% | -1,016.6% | -545.9% | -869.6% |
| Free cash flow margin | 12.5% | -1.9% | 2.3% | -59.1% | -85.0% | -139.1% | -190.5% | -920.5% | -541.6% | -789.4% |
| Return on equity (ROE) | 39.8% | -414.6% | — | — | -145.0% | -84.5% | -61.6% | -58.5% | -27.8% | -44.6% |
| Return on assets (ROA) | 6.3% | -6.6% | -11.5% | -31.9% | -23.4% | -25.2% | -37.0% | -48.4% | -24.6% | -32.5% |
| Debt / equity | — | — | — | — | 1.15 | 0.19 | — | — | — | — |
| Current ratio | 2.76 | 2.78 | 3.08 | 3.51 | 4.04 | 4.47 | 4.87 | 6.69 | 12.23 | 5.10 |
| Revenue growth | 65.2% | 23.0% | 76.2% | 22.9% | 71.3% | 124.3% | 193.4% | -16.7% | 90.7% | — |